ASCO 2026

News

ASCO26: Big win for Erleada in perioperative prostate cancer

ASCO today brings good news for patients with localised prostate cancer, as early use of J&J's ARPI offers a 19 month increase in median survival.

News

ASCO26: Ivonescimab improves survival in NSCLC

Akeso and Summit's PD-1xVEGF drug ivonescimab has improved survival in the HARMONi-6 trial, throwing down a marker for the emerging class.

News

ASCO26: Lilly's Retevmo aces early-stage lung cancer trial

Lilly looks set to extend the reach of RET inhibitor Retevmo in RET+ lung cancer, as the LIBRETTO-432 trial shows its value as adjuvant therapy.

Oncology

Interview at ASCO 26 with David Spetzler

ASCO26: AI supercharging gene-based cancer detection, with D...

Pharmaphorum caught up with Caris Life Science's David Spetzler to talk about how agentic AI is empowering whole genome sequencing in cancer detection

News

ASCO26: BMS hails "compelling" phase 3 celmod readout

Bristol Myers Squibb has high hopes for its celmod drugs, and a phase 3 trial for mezigdomide in multiple myeloma at ASCO26 has delivered the goods.

News

Ahead of ASCO data drop, AZ gets key Imfinzi approval

AstraZeneca has claimed another key FDA approval for Imfinzi in bladder cancer, as an add-on to BCG therapy for early non-muscle invasive disease.

ASCO26: Big win for Erleada in perioperative prostate cancer

ASCO26: Ivonescimab improves survival in NSCLC

ASCO26: Lilly's Retevmo aces early-stage lung cancer trial

ASCO26: AI supercharging gene-based cancer detection, with D...

ASCO26: BMS hails "compelling" phase 3 celmod readout

Ahead of ASCO data drop, AZ gets key Imfinzi approval

BioMarin snaps up Alesta's lead asset for $275M

Discover a new era of healthcare panel engagement: Grounded ...

ASCO 2026

Editor's Picks